Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TRIB1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TRIB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TRIB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TRIB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TRIB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TRIB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TRIB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051403111 | Thyroid | PTC | stress-activated MAPK cascade | 108/5968 | 239/18723 | 1.02e-05 | 1.13e-04 | 108 |
GO:0030099113 | Thyroid | PTC | myeloid cell differentiation | 160/5968 | 381/18723 | 1.75e-05 | 1.82e-04 | 160 |
GO:005109016 | Thyroid | PTC | regulation of DNA-binding transcription factor activity | 178/5968 | 440/18723 | 7.63e-05 | 6.54e-04 | 178 |
GO:000283114 | Thyroid | PTC | regulation of response to biotic stimulus | 136/5968 | 327/18723 | 1.22e-04 | 9.69e-04 | 136 |
GO:000725419 | Thyroid | PTC | JNK cascade | 73/5968 | 167/18723 | 8.41e-04 | 5.17e-03 | 73 |
GO:001481212 | Thyroid | PTC | muscle cell migration | 50/5968 | 110/18723 | 1.93e-03 | 1.04e-02 | 50 |
GO:00434057 | Thyroid | PTC | regulation of MAP kinase activity | 75/5968 | 177/18723 | 2.04e-03 | 1.09e-02 | 75 |
GO:00149095 | Thyroid | PTC | smooth muscle cell migration | 44/5968 | 97/18723 | 3.65e-03 | 1.76e-02 | 44 |
GO:0045862210 | Thyroid | goiters | positive regulation of proteolysis | 28/497 | 372/18723 | 8.12e-07 | 4.73e-05 | 28 |
GO:1903362210 | Thyroid | goiters | regulation of cellular protein catabolic process | 22/497 | 255/18723 | 1.35e-06 | 7.39e-05 | 22 |
GO:0042176210 | Thyroid | goiters | regulation of protein catabolic process | 26/497 | 391/18723 | 1.84e-05 | 7.00e-04 | 26 |
GO:1903050210 | Thyroid | goiters | regulation of proteolysis involved in cellular protein catabolic process | 17/497 | 221/18723 | 9.04e-05 | 2.90e-03 | 17 |
GO:0010498210 | Thyroid | goiters | proteasomal protein catabolic process | 27/497 | 490/18723 | 3.03e-04 | 7.94e-03 | 27 |
GO:0051348210 | Thyroid | goiters | negative regulation of transferase activity | 18/497 | 268/18723 | 3.10e-04 | 8.09e-03 | 18 |
GO:000276312 | Thyroid | goiters | positive regulation of myeloid leukocyte differentiation | 7/497 | 58/18723 | 8.30e-04 | 1.80e-02 | 7 |
GO:0061136210 | Thyroid | goiters | regulation of proteasomal protein catabolic process | 13/497 | 187/18723 | 1.51e-03 | 2.86e-02 | 13 |
GO:004232628 | Thyroid | goiters | negative regulation of phosphorylation | 21/497 | 385/18723 | 1.56e-03 | 2.93e-02 | 21 |
GO:0045639110 | Thyroid | goiters | positive regulation of myeloid cell differentiation | 9/497 | 103/18723 | 1.68e-03 | 3.05e-02 | 9 |
GO:0045936210 | Thyroid | goiters | negative regulation of phosphate metabolic process | 23/497 | 441/18723 | 1.71e-03 | 3.07e-02 | 23 |
GO:0010563210 | Thyroid | goiters | negative regulation of phosphorus metabolic process | 23/497 | 442/18723 | 1.76e-03 | 3.14e-02 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRIB1 | SNV | Missense_Mutation | | c.616N>G | p.Leu206Val | p.L206V | Q96RU8 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TRIB1 | SNV | Missense_Mutation | | c.1015N>A | p.Glu339Lys | p.E339K | Q96RU8 | protein_coding | tolerated(0.45) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TRIB1 | SNV | Missense_Mutation | rs138022510 | c.947G>A | p.Arg316His | p.R316H | Q96RU8 | protein_coding | deleterious(0.03) | probably_damaging(0.986) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
TRIB1 | SNV | Missense_Mutation | | c.424N>C | p.Asn142His | p.N142H | Q96RU8 | protein_coding | tolerated(0.53) | benign(0.115) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TRIB1 | insertion | Frame_Shift_Ins | novel | c.565_566insACCC | p.Ile189AsnfsTer22 | p.I189Nfs*22 | Q96RU8 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TRIB1 | insertion | Nonsense_Mutation | novel | c.566_567insTTGGGTATTTGCAAGTCTAGAGCTTTAGG | p.Val190TrpfsTer9 | p.V190Wfs*9 | Q96RU8 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TRIB1 | insertion | Frame_Shift_Ins | novel | c.742_743insCTTGTAAGCTCCAGCATTATGAATACTATTTGGGGCTTTGCCTC | p.Tyr248SerfsTer17 | p.Y248Sfs*17 | Q96RU8 | protein_coding | | | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TRIB1 | insertion | Frame_Shift_Ins | novel | c.507dupC | p.Tyr170LeufsTer40 | p.Y170Lfs*40 | Q96RU8 | protein_coding | | | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TRIB1 | SNV | Missense_Mutation | novel | c.974N>G | p.Glu325Gly | p.E325G | Q96RU8 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-ZJ-AB0I-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TRIB1 | SNV | Missense_Mutation | rs776955393 | c.1039A>G | p.Ile347Val | p.I347V | Q96RU8 | protein_coding | tolerated(0.54) | benign(0) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |